Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

Cancer Investigation

Volumn 22, Issue 5, 2004, Pages 706-712

  Safran, Howard ^a,f   Iannitti, David ^a,g   Ramanathan, Ramesh ^b,h   Schwartz, Jonathan D ^c   Steinhoff, Margaret ^a,i   Nauman, Chris ^d   Hesketh, Paul ^d   Rathore, Ritesh ^a,j   Wolf, Robert ^e   Tantravahi, Umadevi ^a,i   Hughes, Marilyn ^a,f   Maia, Chris ^a,g   Pasquariello, Terry ^a,i   Goldstein, Lisa ^a,f   King, Thomas ^a,f   Tsai, James Y ^a,f   Kennedy, Teresa ^a,k  

^a Brown University Oncology Group   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MIRIAM HOSPITAL   (United States)

^g RHODE ISLAND HOSPITAL   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

ⁱ WOMEN AND INFANTS HOSPITAL   (United States)

^j ROGER WILLIAMS MEDICAL CENTER   (United States)

^k BROWN UNIVERSITY   (United States)

more..

Author keywords

HER 2 neu; Herceptin; Pancreatic adenocarcinoma

Indexed keywords

ERYTHROPOIETIN; GEMCITABINE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; CLINICAL ARTICLE; CONFERENCE PAPER; DIARRHEA; FATIGUE; FEMORAL HERNIA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE INFARCTION; MESENTERIC VEIN THROMBOSIS; METASTASIS; NAUSEA; NEUTROPENIA; ONCOGENE NEU; PANCREAS CANCER; PRIORITY JOURNAL; SURVIVAL; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 19944429073     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200032974     Document Type: Conference Paper

References (17)

1. Jemal, A.; Thomas, A.; Murray, T.; Thun, M. Cancer statistics, 2002. CA Cancer J. Clin. 2002, 52 (1), 23-47.
2. Burris, H.A., III; Moore, M.J.; Anderson, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer - a randomized trial. J. Clin. Oncol. 1997, 15 (6), 2403-2413.
3. Coussens, L.; Yang-Feng, T.L.; Liao, Y.C.; Chen, E.; Gray, A.; McGrath, J.; Seeburg, P.H.; Libermann, T.A.; Schlessinger, J.; Francke, U.; Levison, A.; Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985, 250, 1132-1139.
4. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; Press, M.F. Studies of the HER-2 proto-oncogene in human breast and ovarian cancer. Science 1989, 244 (4905), 707-712.
5. Baselga, J.; Tripathy, D.; Mendelsohn, J.; Baughman, S.; Benz, C.C.; Dantis, L.; Sklarin, N.T.; Seidman, A.D.; Hudis, C.A.; Moore, J.; Rosen, P.P.; Twaddell, T.; Henderson, I.C.; Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996, 14 (3), 737-744.
6. Vogel, C.L.; Cobleigh, M.A.; Tripathy, D.; Gutheil, J.C.; Harris, L.N.; Fehrenbacher, L.; Slamon, D.J.; Murphy, M.; Novotny, W.F.; Burchmore, M.; Shak, S.; Stewart, S.J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002, 20 (3), 719-726.
7. Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Kunz, J.; Berger, H.G.; Korc, M. Overexpression of HER-2/neu oncogene in human pancreatic carcinoma. Human Pathol. 1993, 24 (10), 1127-1134.
8. Hall, P.A.; Hughes, C.M.; Staddon, S.L.; Richman, P.I.; Gullick, W.J.; Lemoine, N.R. The c-erbB-2 proto-oncogene in human pancreatic cancer. J. Pathol. 1990, 161 (3), 195-200.
9. Satoh, K.; Sasano, H.; Shimosegawa, T.; Koizumi, M.; Yamazaki, T.; Mochizuki, F.; Kobayashi, N.; Okano, T.; Toyota, T.; Sawai, T. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas. Cancer 1993, 72 (1), 51-56.
10. Lei, S.; Appert, H.E.; Nakata, B.; Domenico, D.R.; Kim, K.; Howard, J.M. Overexpression of HER-2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Pancreatol. 1995, 17 (1), 15-21.
11. Day, J.D.; Digiuseppe, J.A.; Yeo, C.; Lai-Goldman, M.; Anderson, S.M.; Goodman, S.N.; Kern, S.E.; Hruban, R.H. Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Human Pathol. 1996, 27 (2), 119-124.
12. Dugan, M.C.; Dergham, S.T.; Kucway, R.; Sigh, K.; Biernat, L.; Du, W.; Vaitkevicius, V.K.; Crissman, J.D.; Sarkar, F.H. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997, 14 (3), 229-236.
13. Safran, H.; Steinhoff, M.; Mangray, S.; Rathore, R.; King, T.C.; Chai, L.; Berzein, K.; Moore, T.; Iannitti, D.; Reiss, P.; Pasquariello, T.; Akerman, P.; Quirk, D.; Mass, R.; Goldstein, L.; Tantravahi, U. Overexpression of the UER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2001, 24 (5), 496-499.
14. Storniolo, A.M.; Enas, N.H.; Brown, C.A.; Voi, M.; Rothenberg, M.L.; Schilsky, R. An investigational new drug treatment program for patients with gemcitabine. Cancer 1999, 85 (3), 1261-1268.
15. Bunn, P.A., Jr.; Helfrich, B.; Soriano, A.F.; Franklin, W.A.; Varella-Gracia, M.; Hirsch, F.R.; Baron, A.; Zeng, C.; Chan, D.C. Expression of HER-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 2001, 7 (10), 3239-3250.
16. Paik, S.; Hazan, R.; Fisher, E.R.; Sass, R.E.; Fisher, B.; Redmond, C.; Schlessinger, J.; Lippman, M.E.; King, C.R. Pathologic findings from the national surgical adjuvant breast and bowel project: prognostic significance of c-erbB-2 protein overexpression in primary breast cancer. J. Clin. Oncol. 1990, 8 (1), 103-112.
17. Muss, H.B.; Thor, A.D.; Berry, D.A.; Kute, T.; Liu, E.T.; Koerner, F.; Cirrincione, C.T.; Budman, D.R.; Wood, W.C.; Barcos, M.; Hendrson, I.C. c-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 1994, 330 (18), 1260-1266.